Skip to main content
Top
Published in: Virology Journal 1/2014

Open Access 01-12-2014 | Research

Occurrence of genetic modifications in core, 5′UTR and NS5b of HCV associated with viral response to treatment

Authors: Sobia Kanwal, Tariq Mahmood

Published in: Virology Journal | Issue 1/2014

Login to get access

Abstract

Background

It is becoming progressively more understandable that genetic variability of viruses is a major challenge in translating the laboratory findings to clinic. Genetic variability is the underlying cause of variant viral proteins which are not targetable by host immunological machinery.

Methods

500 patients were enrolled in study and amongst them, 451 patients were followed and categorized into two groups on the basis of their treatment response. Group 1 consisting of the 376 patients exhibited SVR while group 2 comprised 75 patients who were non-responders on the basis of viral load as evidenced by Real-Time PCR. Comparative sequence analysis was done between 75 non-responders and 75 responders (randomly picked from 376) by targeting three genomic regions, 5′UTR, core and NS5B and amplified products were directly sequenced and obtained sequences were cleaned, aligned and submitted to GenBank. Maximum Parsimony (MP) method was used for phylogenetic analysis and dendrograms were dragged using MEGA 5. Heterogeneity at nucleotide and amino acid level was determined using software BioEdit and DNAman while phosphorylation and N-linked glycosylation sites were determined using NetPhos 2.0 and SignalP-NN.

Results

Genotype 3 was prevalent in group 1 whereas non-responders indicated rare genotypes of Pakistan i.e. 4 and 5, genotype 6q and 6v were reported first time from Pakistan in this study. At nucleotide and amino acid level, the genetic distance and mutation, number of predicted N-phosphorylation and N-glycosylation sites was higher in group 2 as compared to group 1. Difference in percentage composition of individual amino acids was noted to be different between the two groups.

Conclusions

It can be concluded that heterogeneity both at nucleotide and amino acid level contributed in developing drug resistant phenotype. Moreover, occurrence of rare genotypes might hurdle the way to positive response of conventional treatment. Furthermore, prediction of phosphorylation and glycosylation sites could help in targeting the proper sites for drug designing.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alter MJ: Epidemiology of heaptitis C virus infection. W J Gastroenterol 2007,13(17):2436-2441. 10.3748/wjg.v13.i17.2436 Alter MJ: Epidemiology of heaptitis C virus infection. W J Gastroenterol 2007,13(17):2436-2441. 10.3748/wjg.v13.i17.2436
2.
go back to reference Tan SL: Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience; 2006. Tan SL: Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience; 2006.
3.
go back to reference Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D, Blum HE, Bartenschlager R, Moradpour D: Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 2004, 279: 40835-40843. 10.1074/jbc.M404761200PubMed Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D, Blum HE, Bartenschlager R, Moradpour D: Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 2004, 279: 40835-40843. 10.1074/jbc.M404761200PubMed
4.
go back to reference Balvey T: Structural and functional diversity of viral IRESes. Biochim Biophys Acta 2009, 1789: 542-557. 10.1016/j.bbagrm.2009.07.005 Balvey T: Structural and functional diversity of viral IRESes. Biochim Biophys Acta 2009, 1789: 542-557. 10.1016/j.bbagrm.2009.07.005
5.
go back to reference Lindenbach BD, Rice CM: Flaviviridae: the viruses and their replication. In Fields Virology. Edited by: Knipe DM, Howley PM. Philadelphia: Lippincott Williams and Wilkins; 2001:991-1042. Lindenbach BD, Rice CM: Flaviviridae: the viruses and their replication. In Fields Virology. Edited by: Knipe DM, Howley PM. Philadelphia: Lippincott Williams and Wilkins; 2001:991-1042.
6.
go back to reference Reed KE, Rice CM: Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 2001, 242: 55-84. Reed KE, Rice CM: Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 2001, 242: 55-84.
7.
go back to reference Simmonds P: Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004, 85: 3173-3188. 10.1099/vir.0.80401-0PubMed Simmonds P: Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004, 85: 3173-3188. 10.1099/vir.0.80401-0PubMed
8.
go back to reference Wasley A, Alter MJ: Epidemiology of hepatitis C geographic differences and temporal trends. Semin Liv Dis 2000, 20: 1-16. 10.1055/s-2000-9506 Wasley A, Alter MJ: Epidemiology of hepatitis C geographic differences and temporal trends. Semin Liv Dis 2000, 20: 1-16. 10.1055/s-2000-9506
9.
go back to reference Shoukry NH, Cawthon AG, Walker CM: Cell-mediated immunity and the outcome of hepatitis C virus infection. Ann Rev Microbiol 2004, 58: 391-424. 10.1146/annurev.micro.58.030603.123836 Shoukry NH, Cawthon AG, Walker CM: Cell-mediated immunity and the outcome of hepatitis C virus infection. Ann Rev Microbiol 2004, 58: 391-424. 10.1146/annurev.micro.58.030603.123836
10.
go back to reference Yuan HJ, Jain M, Snow KK, Gale M Jr, Lee WM: Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy. J Viral Hepatol 2010, 17: 208-216. 10.1111/j.1365-2893.2009.01169.x Yuan HJ, Jain M, Snow KK, Gale M Jr, Lee WM: Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy. J Viral Hepatol 2010, 17: 208-216. 10.1111/j.1365-2893.2009.01169.x
11.
go back to reference Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T, Gale M: Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A 2007, 104: 582-587. 10.1073/pnas.0606699104PubMedPubMedCentral Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T, Gale M: Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A 2007, 104: 582-587. 10.1073/pnas.0606699104PubMedPubMedCentral
12.
go back to reference Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V: Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352: 1426-1432. 10.1016/S0140-6736(98)07124-4PubMed Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V: Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352: 1426-1432. 10.1016/S0140-6736(98)07124-4PubMed
13.
go back to reference Aral SO, Fenton KA, Holmes KK: Sexually transmitted diseases in the USA: temporal trends. Sex Transm Infect 2007, 83: 257-266. 10.1136/sti.2007.026245PubMedPubMedCentral Aral SO, Fenton KA, Holmes KK: Sexually transmitted diseases in the USA: temporal trends. Sex Transm Infect 2007, 83: 257-266. 10.1136/sti.2007.026245PubMedPubMedCentral
14.
go back to reference Henry P, Zhiying H, Austin LH, William B: Perinatal Transmission and Viral Evolution of Hepatitis C Virus Quasispecies in Infants Coinfected With HIV. J AIDS 2004, 36: 890-899. Henry P, Zhiying H, Austin LH, William B: Perinatal Transmission and Viral Evolution of Hepatitis C Virus Quasispecies in Infants Coinfected With HIV. J AIDS 2004, 36: 890-899.
15.
go back to reference Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C, Caron PR: Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: The crystal structure provides insights into the mode of unwinding. Struc 1998, 6: 89-100. 10.1016/S0969-2126(98)00010-0 Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C, Caron PR: Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: The crystal structure provides insights into the mode of unwinding. Struc 1998, 6: 89-100. 10.1016/S0969-2126(98)00010-0
16.
go back to reference Khan TS, Rizvi F, Rashid A: Hepatitis C seropositivity among liver disease patients in Hazara, Pakistan. J Ayub Med Coll Abbottabad 2003,15(2):53-55.PubMed Khan TS, Rizvi F, Rashid A: Hepatitis C seropositivity among liver disease patients in Hazara, Pakistan. J Ayub Med Coll Abbottabad 2003,15(2):53-55.PubMed
17.
go back to reference Muhammad N, Jan MA: Frequency of hepatitis “C” in Buner, NWFP. J Coll Physicians Surg Pak 2005, 15: 11-14.PubMed Muhammad N, Jan MA: Frequency of hepatitis “C” in Buner, NWFP. J Coll Physicians Surg Pak 2005, 15: 11-14.PubMed
18.
go back to reference Khan H, Zarif M: Risk factors, complications and prognosis of cirrhosis in a tertiary care hospital of peshawer. Hepat Monthly 2006,6(1):7-10. Khan H, Zarif M: Risk factors, complications and prognosis of cirrhosis in a tertiary care hospital of peshawer. Hepat Monthly 2006,6(1):7-10.
19.
go back to reference Bissell DM: Sex and hepatic fibrosis. Hepatol 1999,29(3):988-989. 10.1002/hep.510290351 Bissell DM: Sex and hepatic fibrosis. Hepatol 1999,29(3):988-989. 10.1002/hep.510290351
20.
go back to reference Seeff LB: Natural history of hepatitis C. Hepatol 1997, 26: 21S-28S. 10.1002/hep.510260704 Seeff LB: Natural history of hepatitis C. Hepatol 1997, 26: 21S-28S. 10.1002/hep.510260704
21.
go back to reference Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997,22(9055):825-832. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997,22(9055):825-832.
22.
go back to reference Al-Moslih MI, Al-Huraibi MA: Prevalence of Hepatitis C virus among patients with liver disease in the republic of Yemem East. Mediter Health J 2001,7(4–5):771-778. Al-Moslih MI, Al-Huraibi MA: Prevalence of Hepatitis C virus among patients with liver disease in the republic of Yemem East. Mediter Health J 2001,7(4–5):771-778.
23.
go back to reference Herrine SK: Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002, 136: 747-757. 10.7326/0003-4819-136-10-200205210-00010PubMed Herrine SK: Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002, 136: 747-757. 10.7326/0003-4819-136-10-200205210-00010PubMed
24.
go back to reference Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341: 556-562. 10.1056/NEJM199908193410802PubMed Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341: 556-562. 10.1056/NEJM199908193410802PubMed
25.
go back to reference Bellentani S, Tiribelli C: The spectrum of liver disease in the general population: lesson from the Dionysus study. J Hepatol 2001,35(4):531-537. 10.1016/S0168-8278(01)00151-9PubMed Bellentani S, Tiribelli C: The spectrum of liver disease in the general population: lesson from the Dionysus study. J Hepatol 2001,35(4):531-537. 10.1016/S0168-8278(01)00151-9PubMed
26.
go back to reference Bell H, Hellum K, Harthug S: Genotype, viral load and age as independent predictors of treatment outcome of interferon-a 2a treatment in patients with chronic hepatitis C. Scand J Infect Dis 1997, 29: 17-22. 10.3109/00365549709008658PubMed Bell H, Hellum K, Harthug S: Genotype, viral load and age as independent predictors of treatment outcome of interferon-a 2a treatment in patients with chronic hepatitis C. Scand J Infect Dis 1997, 29: 17-22. 10.3109/00365549709008658PubMed
27.
go back to reference Bonkovsky HL, Mehta S: Hepatitis C: a review and update. J Am Acad Dermatol 2001,44(2):159-182. 10.1067/mjd.2001.109311PubMed Bonkovsky HL, Mehta S: Hepatitis C: a review and update. J Am Acad Dermatol 2001,44(2):159-182. 10.1067/mjd.2001.109311PubMed
28.
go back to reference Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, Aupérin A, Degott C, Benhamou JP, Erlinger S, Marcellin P: Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998, 29: 214-223. 10.1016/S0168-8278(98)80006-8PubMed Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, Aupérin A, Degott C, Benhamou JP, Erlinger S, Marcellin P: Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998, 29: 214-223. 10.1016/S0168-8278(98)80006-8PubMed
29.
go back to reference Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P: Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010,30(9):1259-69. 10.1111/j.1478-3231.2010.02283.xPubMedPubMedCentral Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P: Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010,30(9):1259-69. 10.1111/j.1478-3231.2010.02283.xPubMedPubMedCentral
31.
go back to reference Yoshioka K, Kakumu S, Wakita T: Detection of hepatitis C virus by polymerase chain reaction and response to interferon-a therapy: relationship to genotypes of hepatitis C virus. Hepatol 1992, 16: 293-299. 10.1002/hep.1840160203 Yoshioka K, Kakumu S, Wakita T: Detection of hepatitis C virus by polymerase chain reaction and response to interferon-a therapy: relationship to genotypes of hepatitis C virus. Hepatol 1992, 16: 293-299. 10.1002/hep.1840160203
32.
go back to reference Hayashi J, Kawakami Y, Nabeshima A: Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Dig Dis Sci 1998, 43: 384-391. 10.1023/A:1018874910195PubMed Hayashi J, Kawakami Y, Nabeshima A: Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Dig Dis Sci 1998, 43: 384-391. 10.1023/A:1018874910195PubMed
33.
go back to reference Dalgard O, Bjoro K, Hellum KB: Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatol 2004, 40: 1260-1265. 10.1002/hep.20467 Dalgard O, Bjoro K, Hellum KB: Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatol 2004, 40: 1260-1265. 10.1002/hep.20467
34.
go back to reference Von Wagner M, Huber M, Berg T: Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterol 2005, 129: 522-527. 10.1016/j.gastro.2005.05.008 Von Wagner M, Huber M, Berg T: Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterol 2005, 129: 522-527. 10.1016/j.gastro.2005.05.008
35.
go back to reference Kakumu S, Aiyama T, Okumura A, Iwata K, Ishikawa T, Yoshioka K: Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol 1997,12(6):468-472. 10.1111/j.1440-1746.1997.tb00468.xPubMed Kakumu S, Aiyama T, Okumura A, Iwata K, Ishikawa T, Yoshioka K: Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol 1997,12(6):468-472. 10.1111/j.1440-1746.1997.tb00468.xPubMed
36.
go back to reference Vrolijk JM, de Knegt RJ, Veldt BJ, Orlent H, Schalm SW: The treatment of hepatitis C: history, presence and future. Neth J Med 2004, 62: 76-82.PubMed Vrolijk JM, de Knegt RJ, Veldt BJ, Orlent H, Schalm SW: The treatment of hepatitis C: history, presence and future. Neth J Med 2004, 62: 76-82.PubMed
37.
go back to reference Ahmad S, Salati SAA, Mattar EH, Al-Sabban AMH, Hamad AM: Epidemiology of Hepatitis C Virus (HCV) Infection. Phys Acad 2010, 4: 82-87. Ahmad S, Salati SAA, Mattar EH, Al-Sabban AMH, Hamad AM: Epidemiology of Hepatitis C Virus (HCV) Infection. Phys Acad 2010, 4: 82-87.
38.
go back to reference Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345: 41-52. 10.1056/NEJM200107053450107PubMed Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345: 41-52. 10.1056/NEJM200107053450107PubMed
39.
go back to reference Poynard T, Yuen MF, Ratziu V, Lai CL: Viral hepatitis C. Lancet 2003, 362: 2095-2100. 10.1016/S0140-6736(03)15109-4PubMed Poynard T, Yuen MF, Ratziu V, Lai CL: Viral hepatitis C. Lancet 2003, 362: 2095-2100. 10.1016/S0140-6736(03)15109-4PubMed
40.
go back to reference Abbas SZ, Al M, Muhammad AH, Shaw S, Abba SQ: Frequency of HCV infection and its genotypes among patients attending a liver clinic and voluntary blood donors in a rural area of Pakistan. Pak J Med Sci 2009, 25: 579-582. Abbas SZ, Al M, Muhammad AH, Shaw S, Abba SQ: Frequency of HCV infection and its genotypes among patients attending a liver clinic and voluntary blood donors in a rural area of Pakistan. Pak J Med Sci 2009, 25: 579-582.
41.
go back to reference Moatter T, Hussainy AS, Hamid S, Ahmad Z, Siddiqui S: Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3. Int J Infect Dis 2002, 6: 272-276. 10.1016/S1201-9712(02)90160-8PubMed Moatter T, Hussainy AS, Hamid S, Ahmad Z, Siddiqui S: Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3. Int J Infect Dis 2002, 6: 272-276. 10.1016/S1201-9712(02)90160-8PubMed
42.
go back to reference Khokhar N, Asif N, Khokhar OS: Serotype 3 is most common hepatitis C serotype in Pakistan. However, significant numbers are untypeable. Hepatol 2003,38(1):271-272. 10.1053/jhep.2003.50292 Khokhar N, Asif N, Khokhar OS: Serotype 3 is most common hepatitis C serotype in Pakistan. However, significant numbers are untypeable. Hepatol 2003,38(1):271-272. 10.1053/jhep.2003.50292
43.
go back to reference Afridi S, Naeem M, Hussain A, Kakar N, Babar ME, Ahmad J: Prevalence of hepatitis C virus (HCV) genotypes in Balochistan. Mol Biol Rep 2009,36(6):1511-1514. 10.1007/s11033-008-9342-0PubMed Afridi S, Naeem M, Hussain A, Kakar N, Babar ME, Ahmad J: Prevalence of hepatitis C virus (HCV) genotypes in Balochistan. Mol Biol Rep 2009,36(6):1511-1514. 10.1007/s11033-008-9342-0PubMed
44.
go back to reference Bostan N: Molecular epidemiology and genetic characterization of Hepatitis C Virus in patients from suburban Rawalpindi, Pakistan. DRSM library, Plant Department, Biological Sciences, QAU 2010. Bostan N: Molecular epidemiology and genetic characterization of Hepatitis C Virus in patients from suburban Rawalpindi, Pakistan. DRSM library, Plant Department, Biological Sciences, QAU 2010.
45.
go back to reference Akbar H, Idrees M, Manzoor S, Rehman I, Butt S, Butt S, Yousaf MZ, Rafique S, Awan Z, Khubaib B, Akram M, Aftab M: Hepatitis C virus infection: A review of the current and future aspects and concerns in Pakistan. J Gen Mol Virol 2009, 1: 012-018. Akbar H, Idrees M, Manzoor S, Rehman I, Butt S, Butt S, Yousaf MZ, Rafique S, Awan Z, Khubaib B, Akram M, Aftab M: Hepatitis C virus infection: A review of the current and future aspects and concerns in Pakistan. J Gen Mol Virol 2009, 1: 012-018.
46.
go back to reference Iqbal S, Ahmed R, Yousaf MH, Mumtaz A, Amin D: HCV infected patients; assessment of major genotypes and subtypes of hepatitis C virus. Profession Med J 2007, 14: 266-271. Iqbal S, Ahmed R, Yousaf MH, Mumtaz A, Amin D: HCV infected patients; assessment of major genotypes and subtypes of hepatitis C virus. Profession Med J 2007, 14: 266-271.
47.
go back to reference Idrees M, Riazuddin S: Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infec Dis 2008, 8: 69. 10.1186/1471-2334-8-69 Idrees M, Riazuddin S: Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infec Dis 2008, 8: 69. 10.1186/1471-2334-8-69
48.
go back to reference Idrees M, Lal A, Naseem M, Khalid M: High prevalence of hepatitis C virus infection in the largest province of Pakistan. J Dig Dis 2008, 9: 95-103. 10.1111/j.1751-2980.2008.00329.xPubMed Idrees M, Lal A, Naseem M, Khalid M: High prevalence of hepatitis C virus infection in the largest province of Pakistan. J Dig Dis 2008, 9: 95-103. 10.1111/j.1751-2980.2008.00329.xPubMed
49.
go back to reference Pawlotsky JM: Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003, 7: 45-66. 10.1016/S1089-3261(02)00065-XPubMed Pawlotsky JM: Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003, 7: 45-66. 10.1016/S1089-3261(02)00065-XPubMed
50.
go back to reference Qazi MA, Fayyaz M, Chaudhary GMD, Jamil A, Malik AH, Gardezi AI, Bukhari MH: Hepatitis C virus genotypes in Bahawalpur. Biomedica 2006, 22: 51-54. Qazi MA, Fayyaz M, Chaudhary GMD, Jamil A, Malik AH, Gardezi AI, Bukhari MH: Hepatitis C virus genotypes in Bahawalpur. Biomedica 2006, 22: 51-54.
51.
go back to reference Husain A, Malik FA, Nagra H, Ehsan A, Ahmad Z, Abid M: Frequency of different HCV genotypes in Faisalabad. APMC 2009, 3: 19-22. Husain A, Malik FA, Nagra H, Ehsan A, Ahmad Z, Abid M: Frequency of different HCV genotypes in Faisalabad. APMC 2009, 3: 19-22.
52.
go back to reference Germer JJ, Rys PN, Thorvilson JN, Persing DH: Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999, 37: 2625-2630.PubMedPubMedCentral Germer JJ, Rys PN, Thorvilson JN, Persing DH: Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999, 37: 2625-2630.PubMedPubMedCentral
53.
go back to reference Ziyaeyan M, Alborzi A, Jamalidoust M, Badiee P, Moeini M, Kadivar A: Prevalence of hepatitis C virus genotypes in chronic infected patients, southern Iran. JJM 2011,4(3):141-146. Ziyaeyan M, Alborzi A, Jamalidoust M, Badiee P, Moeini M, Kadivar A: Prevalence of hepatitis C virus genotypes in chronic infected patients, southern Iran. JJM 2011,4(3):141-146.
54.
go back to reference Inamullah , Idrees M, Ahmed H, Sajid-ul-Ghafoor , Ali M, Ali L, Ahmed A: Hepatitis C virus genotypes circulating in district Swat of Khyber Pakhtoonkhaw, Pakistan. Virol J 2011, 8: 16. 10.1186/1743-422X-8-16PubMedPubMedCentral Inamullah , Idrees M, Ahmed H, Sajid-ul-Ghafoor , Ali M, Ali L, Ahmed A: Hepatitis C virus genotypes circulating in district Swat of Khyber Pakhtoonkhaw, Pakistan. Virol J 2011, 8: 16. 10.1186/1743-422X-8-16PubMedPubMedCentral
55.
go back to reference Attaullah S, Khan S, Ali I: Hepatitis C virus genotypes in Pakistan: a systemic review. Viroloy J 2011, 8: 433. 10.1186/1743-422X-8-433 Attaullah S, Khan S, Ali I: Hepatitis C virus genotypes in Pakistan: a systemic review. Viroloy J 2011, 8: 433. 10.1186/1743-422X-8-433
56.
go back to reference Mangia A, Mottola L: Treatment of Non-Genotype 1 Hepatitis C Virus Patients. Curr Gastroenterol Rep 2012, 14: 87-93. 10.1007/s11894-011-0235-3PubMed Mangia A, Mottola L: Treatment of Non-Genotype 1 Hepatitis C Virus Patients. Curr Gastroenterol Rep 2012, 14: 87-93. 10.1007/s11894-011-0235-3PubMed
58.
go back to reference Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lanc Infect Dis 2005, 5: 558-567. 10.1016/S1473-3099(05)70216-4 Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lanc Infect Dis 2005, 5: 558-567. 10.1016/S1473-3099(05)70216-4
59.
go back to reference Yuen MF, Lai CL: Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 2006, 49: 96-98. 10.1159/000087270PubMed Yuen MF, Lai CL: Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 2006, 49: 96-98. 10.1159/000087270PubMed
60.
go back to reference Kamal SM: Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int 2011, 1: 45-52. Kamal SM: Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int 2011, 1: 45-52.
61.
go back to reference el-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O: Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996, 3: 261-264. 10.1111/j.1365-2893.1996.tb00052.xPubMed el-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O: Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996, 3: 261-264. 10.1111/j.1365-2893.1996.tb00052.xPubMed
62.
go back to reference Genovese D, Dettori S, Argentini C, Villano U, Chionne P: Molecular Epidemiology of Hepatitis C Virus Genotype 4 Isolates in Egypt and Analysis of the Variability of Envelope Proteins E1 and E2 in Patients with Chronic Hepatitis. J Clin Microbiol 2005, 43: 1902-1909. 10.1128/JCM.43.4.1902-1909.2005PubMedPubMedCentral Genovese D, Dettori S, Argentini C, Villano U, Chionne P: Molecular Epidemiology of Hepatitis C Virus Genotype 4 Isolates in Egypt and Analysis of the Variability of Envelope Proteins E1 and E2 in Patients with Chronic Hepatitis. J Clin Microbiol 2005, 43: 1902-1909. 10.1128/JCM.43.4.1902-1909.2005PubMedPubMedCentral
63.
go back to reference Chamberlain R, Adams W, Saeed N, Simmonds AA, Elliott P: Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 1997, 78: 1341-1347.PubMed Chamberlain R, Adams W, Saeed N, Simmonds AA, Elliott P: Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 1997, 78: 1341-1347.PubMed
64.
go back to reference Abdulkarim AS, Zein NN, Germer JJ, Kolbert CP, Kabbani L, Krajnik KL, Hola A, Agha MN, Tourogman M, Persing DH: Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from SySria: Identification of two novel hepatitis C virus subtypes. Am J Trop Med Hyg 1998, 59: 571-576.PubMed Abdulkarim AS, Zein NN, Germer JJ, Kolbert CP, Kabbani L, Krajnik KL, Hola A, Agha MN, Tourogman M, Persing DH: Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from SySria: Identification of two novel hepatitis C virus subtypes. Am J Trop Med Hyg 1998, 59: 571-576.PubMed
65.
go back to reference Kabir A, Alavian SM, Keyvani H: Distribution of hepatitis C virus in patients infected by different sources and its correlation with clinical and virological parameters: A preliminary study. Compar Hepatol 2006, 5: 4-9. 10.1186/1476-5926-5-4 Kabir A, Alavian SM, Keyvani H: Distribution of hepatitis C virus in patients infected by different sources and its correlation with clinical and virological parameters: A preliminary study. Compar Hepatol 2006, 5: 4-9. 10.1186/1476-5926-5-4
66.
go back to reference Hnatyszyn HJ: Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Anti vir Ther 2005, 10: 1-11. Hnatyszyn HJ: Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Anti vir Ther 2005, 10: 1-11.
67.
go back to reference Nguyen MH, Keeffe EB: Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005, 3: S97-101.PubMed Nguyen MH, Keeffe EB: Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005, 3: S97-101.PubMed
68.
go back to reference Simmonds P, Holmes EC, Cha TA, Chan SW, HcOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea HS: Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993, 74: 2391-2399. 10.1099/0022-1317-74-11-2391PubMed Simmonds P, Holmes EC, Cha TA, Chan SW, HcOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea HS: Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993, 74: 2391-2399. 10.1099/0022-1317-74-11-2391PubMed
69.
go back to reference Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P: Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. J Gen Virol 1995, 76: 2493-2507. 10.1099/0022-1317-76-10-2493PubMed Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P: Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. J Gen Virol 1995, 76: 2493-2507. 10.1099/0022-1317-76-10-2493PubMed
70.
go back to reference Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC: Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995, 76: 1197-1204. 10.1099/0022-1317-76-5-1197PubMed Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC: Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995, 76: 1197-1204. 10.1099/0022-1317-76-5-1197PubMed
71.
go back to reference Stumpf MPH, Pybus OG: Genetic diversity and models of viral evolution for the hepatitis C virus. FEMS Microbiol Lett 2002, 214: 143-152. 10.1111/j.1574-6968.2002.tb11338.xPubMed Stumpf MPH, Pybus OG: Genetic diversity and models of viral evolution for the hepatitis C virus. FEMS Microbiol Lett 2002, 214: 143-152. 10.1111/j.1574-6968.2002.tb11338.xPubMed
72.
go back to reference Zein NN: Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000, 13: 223-235. 10.1128/CMR.13.2.223-235.2000PubMedPubMedCentral Zein NN: Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000, 13: 223-235. 10.1128/CMR.13.2.223-235.2000PubMedPubMedCentral
73.
go back to reference Khan N, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, Hamid S, Jafri W, Mizokami M: Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol 2009, 18: 1189-1197. Khan N, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, Hamid S, Jafri W, Mizokami M: Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol 2009, 18: 1189-1197.
74.
go back to reference Smith DB, Pathirana S, Davidson F, Lawlor E, Power J: The origin of hepatitis C virus genotypes. J Gen Virol 1997, 78: 321-328.PubMed Smith DB, Pathirana S, Davidson F, Lawlor E, Power J: The origin of hepatitis C virus genotypes. J Gen Virol 1997, 78: 321-328.PubMed
75.
go back to reference Carrington CV, Foster JE, Pybus OG, Bennett SN, Holmes EC: Invasion and maintenance of dengue virus type 2 and type 4 in the Americas. J Virol 2005, 79: 14680-14687. 10.1128/JVI.79.23.14680-14687.2005PubMedPubMedCentral Carrington CV, Foster JE, Pybus OG, Bennett SN, Holmes EC: Invasion and maintenance of dengue virus type 2 and type 4 in the Americas. J Virol 2005, 79: 14680-14687. 10.1128/JVI.79.23.14680-14687.2005PubMedPubMedCentral
76.
go back to reference Oonk G: Global Indian Diasporas: Exploring Trajectories of Migration and Theory. Armsterdam: University press; 2007. Oonk G: Global Indian Diasporas: Exploring Trajectories of Migration and Theory. Armsterdam: University press; 2007.
77.
go back to reference Collier S, Skidmore TE, Blakemore H: The Cambridge Encyclopedia of Latin America and the Caribbean. Cambridge: Cambridge University Press; 1994. Collier S, Skidmore TE, Blakemore H: The Cambridge Encyclopedia of Latin America and the Caribbean. Cambridge: Cambridge University Press; 1994.
78.
go back to reference Pybus OG, Barnes E, Taggart R, Lemey P, Markov PV, Rasachak B, Syhavong B, Phetsouvanah R, Sheridan I, Humphreys IS, Lu L, Newton PN, Klenerman P: Genetic History of Hepatitis C Virus in East Asia. J Virol 2009, 83: 1071-1082. 10.1128/JVI.01501-08PubMedPubMedCentral Pybus OG, Barnes E, Taggart R, Lemey P, Markov PV, Rasachak B, Syhavong B, Phetsouvanah R, Sheridan I, Humphreys IS, Lu L, Newton PN, Klenerman P: Genetic History of Hepatitis C Virus in East Asia. J Virol 2009, 83: 1071-1082. 10.1128/JVI.01501-08PubMedPubMedCentral
79.
go back to reference Domingo E, Holland JJ: Mutation rates and rapid evolution of RNA viruses. In The Evolutionary Biology of Viruses. Edited by: Morse S. New York: Raven Press; 1994:161-183. Domingo E, Holland JJ: Mutation rates and rapid evolution of RNA viruses. In The Evolutionary Biology of Viruses. Edited by: Morse S. New York: Raven Press; 1994:161-183.
80.
go back to reference Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267: 483-489. 10.1126/science.7824947PubMed Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267: 483-489. 10.1126/science.7824947PubMed
81.
go back to reference Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Goudeau A, Lunel-Fabiani F: Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol 2007, 13: 2416-2426. 10.3748/wjg.v13.i17.2416PubMedPubMedCentral Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Goudeau A, Lunel-Fabiani F: Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol 2007, 13: 2416-2426. 10.3748/wjg.v13.i17.2416PubMedPubMedCentral
82.
go back to reference Bukh J, Miller RH, Purcell RH: Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995, 15: 41-63. 10.1055/s-2007-1007262PubMed Bukh J, Miller RH, Purcell RH: Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995, 15: 41-63. 10.1055/s-2007-1007262PubMed
83.
go back to reference Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D: Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 2002, 99: 3081-3086. 10.1073/pnas.052712599PubMedPubMedCentral Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D: Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 2002, 99: 3081-3086. 10.1073/pnas.052712599PubMedPubMedCentral
84.
go back to reference Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N: Characteristic mutations in hepatitis virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci 2009, 100: 2465-2468. 10.1111/j.1349-7006.2009.01338.xPubMed Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N: Characteristic mutations in hepatitis virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci 2009, 100: 2465-2468. 10.1111/j.1349-7006.2009.01338.xPubMed
85.
go back to reference Pazienza V, Vinciguerra M, Andriulli A, Mangia A: Hepatitis C Virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol 2010, 91: 1678-1686. 10.1099/vir.0.020644-0PubMed Pazienza V, Vinciguerra M, Andriulli A, Mangia A: Hepatitis C Virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol 2010, 91: 1678-1686. 10.1099/vir.0.020644-0PubMed
86.
go back to reference Ciccaglione AR, Stellacci E, Marcantonio C, Muto V, Equestre M, Marsili G: Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J Virol 2007, 81: 202-214. 10.1128/JVI.01011-06PubMedPubMedCentral Ciccaglione AR, Stellacci E, Marcantonio C, Muto V, Equestre M, Marsili G: Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J Virol 2007, 81: 202-214. 10.1128/JVI.01011-06PubMedPubMedCentral
87.
go back to reference Lohmann V, Roos A, Korner F, Koch JO, Bartenschlager R: Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J Viral Hepat 2000, 7: 167-174. 10.1046/j.1365-2893.2000.00218.xPubMed Lohmann V, Roos A, Korner F, Koch JO, Bartenschlager R: Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J Viral Hepat 2000, 7: 167-174. 10.1046/j.1365-2893.2000.00218.xPubMed
88.
go back to reference Itakura J, Nagayama K, Enomoto N, Hamano K, Sakamoto N, Fanning LJ, Kenny-Walsh E, Shanahan F, Watanabe M: Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin. J Viral Hepat 2005, 12: 594-603. 10.1111/j.1365-2893.2005.00645.xPubMed Itakura J, Nagayama K, Enomoto N, Hamano K, Sakamoto N, Fanning LJ, Kenny-Walsh E, Shanahan F, Watanabe M: Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin. J Viral Hepat 2005, 12: 594-603. 10.1111/j.1365-2893.2005.00645.xPubMed
89.
go back to reference Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Na’jera I: Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008, 61: 1205-1216. 10.1093/jac/dkn085PubMed Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Na’jera I: Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008, 61: 1205-1216. 10.1093/jac/dkn085PubMed
90.
go back to reference Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y: Mutations in the NS5B region of the hepatitis Cvirus genome correlate with clinical outcomes of interferon-alpha plus ribavirincombination therapy. J Gastroenterol Hepatol 2005, 20: 1401-1409. 10.1111/j.1440-1746.2005.04024.xPubMed Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y: Mutations in the NS5B region of the hepatitis Cvirus genome correlate with clinical outcomes of interferon-alpha plus ribavirincombination therapy. J Gastroenterol Hepatol 2005, 20: 1401-1409. 10.1111/j.1440-1746.2005.04024.xPubMed
91.
go back to reference Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H: Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007, 46: 403-410. 10.1016/j.jhep.2006.09.019PubMed Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H: Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007, 46: 403-410. 10.1016/j.jhep.2006.09.019PubMed
92.
go back to reference Pawlotsky JM, McHutchison JG: Hepatitis C: Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference. Chicago, IL, February 27–March 1, 2003. Hepatology 2004, 39: 554-567. 10.1002/hep.20065PubMed Pawlotsky JM, McHutchison JG: Hepatitis C: Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference. Chicago, IL, February 27–March 1, 2003. Hepatology 2004, 39: 554-567. 10.1002/hep.20065PubMed
93.
go back to reference Di Marco S, Volpari C, Tomei L, Altamura S, Harper S: Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 2005, 280: 29765-29770. 10.1074/jbc.M505423200PubMed Di Marco S, Volpari C, Tomei L, Altamura S, Harper S: Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 2005, 280: 29765-29770. 10.1074/jbc.M505423200PubMed
94.
go back to reference Ma H, Leveque V, De Witte A, Li W, Hendricks T, Clausen SM, Cammack N, Klumpp K: Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors. Virology 2005, 332: 8-15. 10.1016/j.virol.2004.11.024PubMed Ma H, Leveque V, De Witte A, Li W, Hendricks T, Clausen SM, Cammack N, Klumpp K: Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors. Virology 2005, 332: 8-15. 10.1016/j.virol.2004.11.024PubMed
95.
go back to reference Pawlotsky JM: Therapy of hepatitis C: from empiricism to cure. Hepatology 2006, 43: S207-S220. 10.1002/hep.21064PubMed Pawlotsky JM: Therapy of hepatitis C: from empiricism to cure. Hepatology 2006, 43: S207-S220. 10.1002/hep.21064PubMed
96.
go back to reference Grandvaux N, tenOever BR, Servant MJ, Hiscott J: The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 2002, 15: 259-267. 10.1097/00001432-200206000-00008PubMed Grandvaux N, tenOever BR, Servant MJ, Hiscott J: The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 2002, 15: 259-267. 10.1097/00001432-200206000-00008PubMed
97.
go back to reference Clemens MJ: PKR–a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol 1997, 29: 945-949. 10.1016/S1357-2725(96)00169-0PubMed Clemens MJ: PKR–a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol 1997, 29: 945-949. 10.1016/S1357-2725(96)00169-0PubMed
98.
go back to reference Lee SB, Bablanian R, Esteban M: Regulated expression of the interferon-induced protein kinase p68 (PKR) by vaccinia virus recombinants inhibits the replication of vesicular stomatitis virus but not that of poliovirus. J Interferon Cytokine Res 1996, 16: 1073-1078.PubMed Lee SB, Bablanian R, Esteban M: Regulated expression of the interferon-induced protein kinase p68 (PKR) by vaccinia virus recombinants inhibits the replication of vesicular stomatitis virus but not that of poliovirus. J Interferon Cytokine Res 1996, 16: 1073-1078.PubMed
99.
go back to reference Williams BR: PKR; a sentinel kinase for cellular stress. Oncogene 1999, 18: 6112-6120. 10.1038/sj.onc.1203127PubMed Williams BR: PKR; a sentinel kinase for cellular stress. Oncogene 1999, 18: 6112-6120. 10.1038/sj.onc.1203127PubMed
100.
go back to reference Mathews MB, Hershey JWB, Sonenberg N: Translational Control. New York: Cold Spring Harbor Laboratory Press, Cold Spring Harbor; 1996. Mathews MB, Hershey JWB, Sonenberg N: Translational Control. New York: Cold Spring Harbor Laboratory Press, Cold Spring Harbor; 1996.
101.
go back to reference Guo JT, Bichko VV, Seeger C: Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2011, 75: 8516-8523. Guo JT, Bichko VV, Seeger C: Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2011, 75: 8516-8523.
102.
go back to reference Yan XB, Battaglia S, Boucreux D, Chen Z, Brechot C: Mapping of the interacting domains of hepatitis C virus core protein and the double-stranded RNA-activated protein kinase PKR. Virus Res 2007, 125: 79-87. 10.1016/j.virusres.2006.12.010PubMed Yan XB, Battaglia S, Boucreux D, Chen Z, Brechot C: Mapping of the interacting domains of hepatitis C virus core protein and the double-stranded RNA-activated protein kinase PKR. Virus Res 2007, 125: 79-87. 10.1016/j.virusres.2006.12.010PubMed
103.
go back to reference Land A, Braakman I: Folding of the humanimmunodeficiency virus type 1 envelope glycoprotein in theendoplasmic reticulum. Biochimie 2001, 83: 783-790. 10.1016/S0300-9084(01)01314-1PubMed Land A, Braakman I: Folding of the humanimmunodeficiency virus type 1 envelope glycoprotein in theendoplasmic reticulum. Biochimie 2001, 83: 783-790. 10.1016/S0300-9084(01)01314-1PubMed
104.
go back to reference Slater-Handshy T, Droll DA, Fan X, Di Bisceglie AM, Chambers TJ: HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology 2004, 319: 36-48. 10.1016/j.virol.2003.10.008PubMed Slater-Handshy T, Droll DA, Fan X, Di Bisceglie AM, Chambers TJ: HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology 2004, 319: 36-48. 10.1016/j.virol.2003.10.008PubMed
105.
go back to reference Vigerust DJ, Virginia L, Shepherd VL: Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 2007, 15: 211-218. 10.1016/j.tim.2007.03.003PubMed Vigerust DJ, Virginia L, Shepherd VL: Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 2007, 15: 211-218. 10.1016/j.tim.2007.03.003PubMed
106.
go back to reference Tamura K, Peterson D, Peterson N, Stecher G: Nei: MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28: 2731-2739. 10.1093/molbev/msr121PubMedPubMedCentral Tamura K, Peterson D, Peterson N, Stecher G: Nei: MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28: 2731-2739. 10.1093/molbev/msr121PubMedPubMedCentral
Metadata
Title
Occurrence of genetic modifications in core, 5′UTR and NS5b of HCV associated with viral response to treatment
Authors
Sobia Kanwal
Tariq Mahmood
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2014
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-11-171

Other articles of this Issue 1/2014

Virology Journal 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.